Please assess the completion status of the following clinical trial:

Trial Title: Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Breast adenocarcinoma treated by neoadjuvant or adjuvant chemotherapy within 12 months prior to study enrollment~* WHO performance status 0-1~* Age ≥18 years old~* Affiliation to a social security regime or beneficiary of equivalent social protection~* Written informed consent provided before any study specific procedures~Complementary inclusion criterion for randomization~- Proved vitamin D deficiency as defined by serum vitamin D level lower than 30 ng/ml (75 nmol/L).~Exclusion Criteria:~* Metastatic disease~* History or presence of any other malignancy (except curatively treated nonmelanoma skin cancer or in situ cervix carcinoma) .............~traités dans les 5 ans précédents.~* Contraindication to calcium or cholecalciferol~* Known severe hypersensitivity to vitamin D or to calcium supplementation or to one of the excipients.~* Disease and/or medical conditions accompanied by hypercalcaemia and/or hypercalciuria~* Calcium lithiasis and tissue calcification~* Hypervitaminosis D~* Presence of significant comorbidities:~  i) Uncontrolled endocrine disease ii) Known disorders of calcium phophorus laboratory testing iii) Proved osteopenia or osteoporosis requiring vitamin D and calcium supplements~* Concomitant treatment with other experimental products or another vitamin D calcium treatment~* Pregnancy, breastfeeding or of reproductive potential not using an effective contraceptive method~* Legal inability or restricted legal ability. Medical or psychological conditions not allowing proper study completion or informed consent signature

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional vitamin D and calcium supplementation (Type: ACTIVE_COMPARATOR): Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
- vitamin D supplementation tailored to vitamin D deficiency (Type: EXPERIMENTAL): Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level \< 30 ng/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).